Early Changes in Inflammatory Indices and Healing in IBD
Early Kinetic Changes in Blood-Based Inflammatory Indices as Predictors of Endoscopic and Histological Healing in Patients With Inflammatory Bowel Disease
This prospective observational study aims to evaluate early changes in blood-based inflammatory indices during the first 4 weeks after treatment initiation or escalation and their relation to endoscopic and histological healing at 12 to 16 weeks in adult patients with inflammatory bowel disease.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
Objective assessment of treatment response is important in inflammatory bowel disease. This prospective cohort study will include adult patients with ulcerative colitis or Crohn's disease who are starting or escalating medical therapy.
Blood-based inflammatory indices will be assessed at baseline and at 4 weeks. Endoscopic and histological outcomes will be evaluated at approximately 12 to 16 weeks.
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Yehia M Alaa, Resident
- Telefonnummer: 01552751879
- E-post: Yehia.18313599@med.aun.edu.eg
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Adult patients with ulcerative colitis or Crohn's disease starting or escalating medical therapy at the Gastroenterology and Hepatology Unit, Assiut University.
Beskrivning
Inclusion Criteria:
- Age 18 years or older
- Confirmed diagnosis of ulcerative colitis or Crohn's disease
- Objective evidence of active disease at baseline
- Planned initiation or escalation of IBD treatment
- Baseline CBC with differential, CRP, and serum albumin available
- Planned follow-up assessment at approximately 12-16 weeks
- Planned follow-up colonoscopy with mucosal biopsies at approximately 12-16 weeks
- Written informed consent
Exclusion Criteria:
- Active infection
- Recent major surgery
- Malignancy
- Hematological malignancy or disorder substantially altering leukocyte or platelet counts
- Significant uncontrolled liver disease
- Severe renal disease expected to substantially affect inflammatory markers
- Recent blood transfusion
- Pregnancy
- Concomitant autoimmune inflammatory disease
- Systemic corticosteroids used for another indication
- Acute severe infection around the time of blood sampling
- Inadequate follow-up or missing essential data
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Single cohort: Adult IBD Patients
Adult patients with ulcerative colitis or Crohn's disease who are starting or escalating medical therapy and will be followed for early changes in inflammatory indices and later endoscopic and histological outcomes. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion of patients with endoscopic healing
Tidsram: 12 to 16 weeks
|
Proportion of patients achieving endoscopic healing at follow-up, defined as Mayo Endoscopic Score = 0 in ulcerative colitis or SES-CD < 3 in Crohn's disease. |
12 to 16 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion of patients with histological healing
Tidsram: 12 to 16 weeks
|
Proportion of patients achieving histological healing based on histopathological assessment of mucosal biopsies. |
12 to 16 weeks
|
|
Mean change in neutrophil-to-lymphocyte ratio
Tidsram: Baseline and at 4 weeks
|
Mean change in neutrophil-to-lymphocyte ratio (NLR) from baseline to 4 weeks. |
Baseline and at 4 weeks
|
|
Mean change in C-reactive protein
Tidsram: Baseline and at 4 weeks
|
Mean change in C-reactive protein (CRP) level from baseline to 4 weeks. |
Baseline and at 4 weeks
|
|
Mean change in CRP-to-albumin ratio
Tidsram: Baseline and at 4 weeks
|
Mean change in CRP-to-albumin ratio (CAR) from baseline to 4 weeks. |
Baseline and at 4 weeks
|
|
Mean change in systemic immune-inflammation index
Tidsram: Baseline and at 4 weeks
|
Mean change in systemic immune-inflammation index (SII) from baseline to 4 weeks. |
Baseline and at 4 weeks
|
|
Mean Mayo Endoscopic Score
Tidsram: 12 to 16 weeks
|
Mean Mayo Endoscopic Score in patients with ulcerative colitis (range 0-3, higher scores indicate more severe endoscopic activity). |
12 to 16 weeks
|
|
Mean SES-CD score
Tidsram: 12 to 16 weeks
|
Mean Simple Endoscopic Score for Crohn's Disease (SES-CD) (higher scores indicate more severe endoscopic activity). |
12 to 16 weeks
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studiestol: Mohamed Z Hagez, prof, Internal Medicine Department, Assiut University Hospitals
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- IBD-Indices-Assiut-2026
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .